Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Wisconsin, Madison
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)